Guangzhou Hanfang Pharmaceutical Company Limited Launches LowImpurity MCT Raw Materials

Domestic Leader Breaks International Monopoly with High-Purity Pharmaceutical Lipids

GUANGZHOU, CHINA, August 6, 2026 – Guangzhou Hanfang Pharmaceutical Company Limited, a leading global provider of high-end pharmaceutical lipid excipients, today announced the official launch of its low-impurity medium chain triglyceride (MCT) raw materials. This product breaks the long-term international monopoly in the high-end pharmaceutical lipid sector, achieving a leap in localization rate from 10% to 90% for such critical materials. Featuring ultra-high purity, eco-friendly production processes, and global compliance certifications, the low-impurity MCT meets strict quality standards for pharmaceutical, nutraceutical, and specialty medical food manufacturers worldwide. The product is now open for global pre-order.

Core Technological Breakthroughs & Product Highlights

The low-impurity MCT raw materials are developed using the company’s proprietary integrated green technology, combining supercritical CO₂ extraction, membrane separation, and chromatographic separation to replace traditional polluting processes. This innovative approach ensures the product meets strict impurity control standards, supporting the production of high-quality injectable formulations, nutraceuticals, and specialty medical foods.

As a key achievement in the company’s technological R&D, the low-impurity MCT received regulatory approval for market launch in 2023, marking a critical milestone in domestic high-end pharmaceutical excipient localization. The product helps reduce pharmaceutical manufacturers’ reliance on imported raw materials, lowering supply chain risks and production costs.

Global Compliance & Certifications

To meet global market access requirements, the low-impurity MCT raw materials have obtained multiple international certifications, including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI. These certifications ensure the product complies with regulatory standards in major markets across Europe, North America, and Asia-Pacific, enabling widespread application in global pharmaceutical and nutraceutical production.

Supply & Customization Services

The low-impurity MCT raw materials are now available for pre-order through Guangzhou Hanfang Pharmaceutical Company Limited’s official website and global authorized distributors. Mass production and global shipping will commence in July 2026. In addition to standard products, the company offers customized processing services tailored to specific customer requirements, including purity adjustments and formulation optimization, to support diverse industry needs.

Authoritative Quotes

"Our low-impurity MCT raw materials address a critical gap in the domestic pharmaceutical supply chain, providing a reliable, high-quality alternative to imported products while adhering to international standards," said Xu Wendong, General Manager and Deputy Director of the National Engineering Research Center at Guangzhou Hanfang Pharmaceutical Company Limited. "This launch reinforces our commitment to technological self-reliance and securing the global pharmaceutical industry chain."

Industry Context & Corporate Strategy

According to industry reports, global demand for high-purity pharmaceutical lipid excipients is growing rapidly, driven by stricter quality regulations and the expansion of biopharmaceutical and nutraceutical sectors. Guangzhou Hanfang Pharmaceutical Company Limited’s launch of low-impurity MCT aligns with this trend, positioning the company as a key player in the global high-end pharmaceutical raw materials market.

Future Plans

Looking ahead, Guangzhou Hanfang Pharmaceutical Company Limited will continue to invest in R&D for high-end pharmaceutical lipid technologies, expanding its product portfolio of localized alternative raw materials. The company also plans to strengthen its global sales and service network to provide localized support to customers in more regions.

Company Profile

Founded in 1998, Guangzhou Hanfang Pharmaceutical Company Limited is a state-owned technology-driven pharmaceutical enterprise under the Guangzhou Pharmaceutical Holdings (GPHL) Group. As a national-level specialized, sophisticated, unique, and new "Little Giant" enterprise, it operates the only national engineering research center for traditional Chinese medicine engineering technology in China. The company specializes in pharmaceutical raw materials, lipid excipients, health products, and technical services, holding over 240 patents and serving more than 1,000 customers worldwide, including B. Braun and AstraZeneca. Its mission is to achieve technological self-reliance, solve "bottleneck" problems, and protect human health.

Contact Information

Company: Guangzhou Hanfang Pharmaceutical Company Limited
Official Website: http://byshanhanfang.com/

© 2026 Guangzhou Hanfang Pharmaceutical Company Limited. All rights reserved.